IP Library Granted Patent US 7,524,676
Granted Patent B2
US 7,524,676 · App. 11/084,485 · Granted Apr 28, 2009

Large scale productions of virus antigen

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,524,676
App. No.
11/084,485
Granted
Apr 28, 2009
Kind
B2
Abstract

The present invention provides improved methods of production of viral antigen on a culture of adherent cells bound to a microcarrier, wherein the methods provide for increased viral antigen yield per culture medium volume. The invention is also directed to a cell culture biomass of adherent cells having increased cell density and microcarrier concentration compared to the respective confluent cell culture.

Claims (10)

1. A concentrated cell culture biomass prepared by growing a cell culture of adherent cells bound to a microcarrier to confluence, and then concentrating the cell culture, wherein cell density and microcarrier concentration of the concentrated cell culture biomass is at least 1.3 fold compared to cell density and microcarrier concentration of said cell culture grown to confluence.

2. The culture according to claim 1 wherein said cells are VERO cells.

3. The culture according to claim 1 wherein said culture is serum free.

4. The culture according to claim 1 wherein said culture is serum and protein free.

5. The culture according to claim 1 wherein said cells are infected with a virus.

6. The culture of claim 5 wherein cell density of the biomass of the infected cells in said cell culture is at least 1.3-fold compared to cell density of said cell culture grown to confluence prior to infection.

7. The cell culture according to claim 5 infected with a virus selected from the group consisting of Influenza virus, Ross River Virus, Hepatitis A Virus, Vaccinia Virus, recombinant Vaccinia Virus, Herpes Simplex Virus, Japanese encephalitis Virus, West Nile Virus, Yellow Fever Virus, chimeric Yellow Fever Virus, Rhinovirus and Reovirus.

8. The cell culture biomass of claim 7 wherein the virus is Influenza virus.

9. The cell culture biomass of claim 7 wherein the virus is Ross River virus.

10. The cell culture biomass of claim 7 wherein the virus is Vaccinia virus.

Assignments (7)
CHANGE OF NAME Recorded Sep 8, 2022
From: OLOGY BIOSERVICES, INC.
To: RESILIENCE GOVERNMENT SERVICES, INC.
Reel/Frame 061399/0903 →
RELEASE OF SECURITY INTEREST Recorded Aug 20, 2020
From: MIDCAP FINANCIAL TRUST, AS AGENT
To: OLOGY BIOSERVICES, INC.; NANO ADM, LLC
Reel/Frame 053561/0070 →
CHANGE OF NAME Recorded Jan 23, 2019
From: NANOTHERAPEUTICS, INC.
To: OLOGY BIOSERVICES, INC.
Reel/Frame 049518/0666 →
SECURITY INTEREST Recorded May 1, 2018
From: OLOGY BIOSERVICES, INC.
To: MIDCAP FINANCIAL TRUST, AS AGENT
Reel/Frame 046050/0305 →
CORRECTIVE ASSIGNMENT TO CORRECT THE CORRESPONDENCE DATA PREVIOUSLY RECORDED ON REEL 037155 FRAME 0732. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded May 2, 2016
From: BAXALTA GMBH
To: NANOTHERAPEUTICS, INC.
Reel/Frame 038592/0044 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 24, 2015
From: BAXALTA GMBH
To: NANOTHERAPEUTICS, INC.
Reel/Frame 037155/0732 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 18, 2015
From: BAXTER HEALTHCARE SA
To: BAXALTA GMBH
Reel/Frame 036388/0070 →